Home > Insider Trading > Filing (0001638599-17-000050)

Filing Details

Accession Number:: 0001638599-17-000050
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-01-09 18:46:08
Reporting Period:: 2017-01-09

Filing Date:: 2017-01-09
Accepted Time:: 2017-01-09 18:46:08
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1404644	Aquinox Pharmaceuticals Inc	AQXP	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1087939	Julian Baker	667 Madison Avenue, 21St Floor New York NY 10065	No	No	Yes	No
1087940	Felix Baker	667 Madison Avenue, 21St Floor New York NY 10065	No	No	Yes	No
1263508	Baker Bros. Advisors Lp	667 Madison Avenue, 21St Floor New York NY 10065	No	No	Yes	No
1580575	Baker Bros. Advisors (Gp) Llc	667 Madision Avenue, 21St Floor New York NY New York	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-01-09	603	$16.74	1,132,228	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2017-01-09	5,697	$16.74	9,410,164	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2017-01-09	1,195	$15.32	1,133,423	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2017-01-09	11,305	$15.32	9,421,469	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2017-01-09	258	$16.85	1,133,681	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2017-01-09	2,442	$16.85	9,423,911	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2017-01-09	917	$15.35	1,134,598	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2017-01-09	8,671	$15.35	9,432,582	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2017-01-09	967	$16.20	1,135,565	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2017-01-09	9,143	$16.20	9,441,725	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2017-01-09	1,602	$15.13	1,137,167	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2017-01-09	15,148	$15.13	9,456,873	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2017-01-09	529	$15.62	1,137,696	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2017-01-09	5,006	$15.62	9,461,879	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2017-01-09	3,739	$16.31	1,141,435	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2017-01-09	35,360	$16.31	9,497,239	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2017-01-09	24,871	$17.60	1,166,306	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2017-01-09	235,169	$17.60	9,732,408	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2017-01-09	3,389	$17.76	1,169,695	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2017-01-09	32,051	$17.76	9,764,459	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,260	Direct
Common Stock	2,260	Direct

Footnotes

Common shares held directly by Felix J. Baker and for which Felix J. Baker has sole beneficial ownership. These shares were received in an in kind pro ratadistribution from an affiliated investment fund in January 2015 without consideration.
Common shares held directly by Julian C. Baker and for which Julian C. Baker has sole beneficial ownership. These shares were received in an in kind pro ratadistribution from an affiliated investment fund in January 2015 without consideration.
The price reported in Column 4 is a weighted average price. These shares were traded by the Funds in multiple transactions at prices ranging from $16.69 to $16.75, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
After giving effect to the transactions reported herein, and as a result of their ownership interest in Baker Biotech Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
After giving effect to the transactions reported herein, and as a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
The price reported in Column 4 is a weighted average price. These shares were traded by the Funds in multiple transactions at prices ranging from $15.26 to $15.46, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were traded by the Funds in multiple transactions at prices ranging from $16.72 to $16.99, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were traded by the Funds in multiple transactions at prices ranging from $15.19 to $15.48, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were traded by the Funds in multiple transactions at prices ranging from $15.75 to $16.75, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were traded by the Funds in multiple transactions at prices ranging from $15.01 to $15.74, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were traded by the Funds in multiple transactions at prices ranging from $15.38 to $15.79, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were traded by the Funds in multiple transactions at prices ranging from $15.81 to $16.80, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were traded by the Funds in multiple transactions at prices ranging from $16.81 to $17.80, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.